

Special Issue

Diagnosis and Control of African Swine Fever Virus (ASFV) Infection

Message from the Guest Editors

African swine fever (ASF) is currently the most threatening disease in domestic and wild pigs worldwide for which there is no commercial vaccine available. The presence of ASF on five continents, including large parts of Asia, makes ASF the worst livestock pandemic of this century. The causal agent, the African swine fever virus (ASFV), is a large and highly complex virus that affects both domestic and wild pigs, such as European and African wild pigs, making it difficult to eradicate in endemic areas with the coexistence of circulating viruses of different virulence. The purpose of this special issue of *Vaccines* is to update knowledge and research on important aspects of the disease related to virus infection, disease dynamics, diagnostic tools, and control strategies. Particular emphasis will be placed on research focused on studies with new vaccine candidates, including the elucidation of vaccine control strategies.

Guest Editors

Dr. Marisa Arias

European Union Reference Laboratory for ASF and FAO Reference Centre for ASF, Centro de Investigación en Sanidad Animal CISA-INIA/CSIC, Valdeolmos, 28130 Madrid, Spain

Dr. Carmina Gallardo

European Union Reference Laboratory for ASF and FAO Reference Centre for ASF, Centro de Investigación en Sanidad Animal CISA-INIA/CSIC, Valdeolmos, 28130 Madrid, Spain

Deadline for manuscript submissions

closed (31 July 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/119567

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).